Pegaldesleukin
Alternative Names: PEG interleukin-2; Proleukin-PEG™Latest Information Update: 24 Oct 2021
At a glance
- Originator Research Corporation Technologies
- Developer Chiron Corporation; Eurocetus; Nonindustrial source; Research Corporation Technologies
- Class Interleukins
- Mechanism of Action Immunostimulants; Interleukin 2 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer metastases; Head and neck cancer; HIV-1 infections; Prostate cancer
Most Recent Events
- 23 Feb 2004 Discontinued - Clinical-Phase-Unknown for HIV-1 infections in France (IV)
- 23 Feb 2004 Discontinued - Phase-I for Head and neck cancer in Netherlands (Intratumoural)
- 23 Feb 2004 Discontinued - Phase-II for Cancer metastases in Netherlands (Intratumoural)